Motixafortide
CAS No. : 664334-36-5
(Synonyms: BKT140 (4-fluorobenzoyl); BL-8040; TF14016)
| Size | Price | Stock |
|---|---|---|
| 5mg | $280 | In-stock |
| 10mg | $450 | In-stock |
| 25mg | $900 | In-stock |
| 50mg | $1350 | In-stock |
| 100mg | $1960 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-P0171 |
| M.Wt: | 2159.52 |
| Formula: | C97H144FN33O19S2 |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 100 mg/mL;H2O : 50 mg/mL (ultrasonic) |
Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC50 vakue of ～1 nM. IC50 & Target:IC50: ～1 nM (CXCR4)[1]. In Vitro:Motixafortide (BKT140) displays selective toxicity toward AmL and MM cells. Treatment with Motixafortide (BKT140) can overcome IL-6 dependent proliferation and survival of ARH77 MM cells. Motixafortide (BKT140) specifically triggers CXCR4-dependent cell death in leukemia and MM cells. Motixafortide (BKT140) stimulates apoptotic cell death in leukemia and MM cells[2]. In Vivo:Subcutaneous injections of Motixafortide (BKT140) significantly reduces, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts. Tumors from animals treated with Motixafortide (BKT140) are smaller in size and weights, had larger necrotic areas and high apoptotic scores[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Motixafortide
- Cat. No.:
- HY-P0171
- Quantity:
Your information is safe with us.